May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The role of zinc–desferrioxamine in preventing lenticular oxygen damage
S. Schaal; I. Beiran; M. Chevion; I. Rubinstein; B. Miller; A. Dovrat
Author Affiliations & Notes
  • S. Schaal
    Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
  • I. Beiran
    Ophthalmology, Rambam Medical Center, Haifa, Israel
  • M. Chevion
    Hadassah Medical School, Hebrew University, Jerusalem, Israel
  • I. Rubinstein
    Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
  • B. Miller
    Ophthalmology, Rambam Medical Center, Haifa, Israel
  • A. Dovrat
    Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
  • Footnotes
    Commercial Relationships  S. Schaal, None; I. Beiran, None; M. Chevion, None; I. Rubinstein, None; B. Miller, None; A. Dovrat, None.
  • Footnotes
    Support  This study was supported, in part, by the Dr. Moshe and Paulina bergman memorial fund.
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 396. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The role of zinc–desferrioxamine in preventing lenticular oxygen damage
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      S. Schaal, I. Beiran, M. Chevion, I. Rubinstein, B. Miller, A. Dovrat; The role of zinc–desferrioxamine in preventing lenticular oxygen damage . Invest. Ophthalmol. Vis. Sci. 2004;45(13):396.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose:To investigate the effects of zinc–desferrioxamine (Zn–DFO) on oxygen induced damage to bovine lenses in organ culture. Methods: Four groups of lenses were studied: (1) 40 lenses exposed daily for 4 days to hyperbaric oxygen (HBO) for 120 minutes 100% oxygen in a pressure chamber at 2.5 ATA. (2) 20 lenses from contralateral eyes of group 1 exposed daily to HBO as described for group 1 kept in a Zn–DFO solution during HBO exposure. (3) 40 lenses exposed daily for 4 days to 100% oxygen at 1 ATA for 120 minutes. (4) 20 lenses from contralateral eyes of group 3 exposed as described for group 3 and kept in a Zn–DFO solution during normobaric oxygen exposure. Lens optical quality was followed during 14 days of culture. Lenses were processed for histochemistry and enzyme analysis. Results:Decreased lenticular optical quality and decreased enzymatic activities were observed in lenses exposed to repetitive 100% oxygen concentration. The magnitude of the observed changes was oxygen load dependent – the higher the oxygen partial pressure and the longer the time of exposure the more severe the changes observed. Addition of Zn–DFO to the organ culture eliminated most of the oxygen–induced damage. The effect of Zn–DFO was oxygen load–dependent. Addition of Zn–DFO resulted in reduced oxidative damage in a time–dependent manner– the later the addition of Zn–DFO the smaller the antioxidative effect observed. Catalase and ATPase activities were enhanced by the addition of Zn–DFO. Conclusions:High oxygen load has a toxic effect on bovine lenses in organ culture. This effect is attenuated by Zn–DFO. The protective effect of Zn–DFO is both time and oxygen load dependent. Enzyme studies indicated enhanced physiological antioxidant activity as a possible mechanism for the effect of Zn–DFO. These results indicate a potential role of Zn–DFO as a protective agent against oxygen–induced cataract formation in humans.

Keywords: cataract • oxidation/oxidative or free radical damage • aging 
© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept